Placental transfer of pyrimethamine studied in an ex vivo placental perfusion model

Biology of the Neonate

Volumn 78, Issue 2, 2000, Pages 83-85

  Peytavin, Gilles ^a   Leng, Jean Joël ^b   Forestier, François ^a,e   Saux, Marie Claude ^c   Hohlfeld, Patrick ^d   Farinotti, Robert ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b HÔPITAL PELLEGRIN   (France)

^c UFR Pharmacie   (France)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e Institut de Puericulture   (France)

Author keywords

Cotyledon clearance; Fetal transfer; Perfusion; Placenta; Pyrimethamine

Indexed keywords

ANTIINFECTIVE AGENT; DAPSONE; FANSIDAR; FOLIC ACID ANTAGONIST; FOLINATE CALCIUM; PHENAZONE; PYRIMETHAMINE; SPIRAMYCIN; SULFANILAMIDE;

ACTIVE TRANSPORT; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DIFFUSION; FEMALE; HUMAN; HUMAN TISSUE; PLACENTA PERFUSION; PLACENTAL TRANSFER; PRIORITY JOURNAL; TOXOPLASMA GONDII; TOXOPLASMOSIS; TRANSPORT KINETICS;

TOXOPLASMA GONDII;

EID: 0033818062     PISSN: 00063126     EISSN: None     Source Type: Journal    
DOI: 10.1159/000014254     Document Type: Article

References (17)

1. Moffat AC: Pyrimethamine; in Clarke GC (ed): Isolation and Identification of Drugs in Pharmaceuticals. Body Fluids, and Post-Mortem Material. Ed Clarke's. London, Pharmaceutical Press, 1986, pp 949-950.
2. Mammen GJ: Clinical Pharmacokinetics. Drug Data Handbook. Pyrimethamine, Berlin, Springer, 1990, p 20.
3. Derouin F, Piketty C, Chastang C, Chau F, Rouveix B, Pocidalo JJ: Anti-Toxoplasma effects of dapsone alone and combined with pyrimethamine. Antimicrob Agents Chemother 1991;35:252-255.
4. Leport C, Meulemans A, Robine D, Dameron G, Vildé JL: Levels of Pyrimethamine in serum and penetration into brain tissue in humans. AIDS 1992;6:1040-1041.
5. Opravil M, Joos B, Lüthy R: Levels of dapsone and pyrimethamine in serum during once-weekly dosing for prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. Antimicrob Agents Chemother 1994;38: 1197-1199.
6. Russo M, Galanti B: Prevenzione della toxoplasmosi congenita. Clin Ter 1990;134:383-392.
7. Desmonts G, Daffos F, Forestier F, Capella-Pavlovsky M. Thulliez P. Chartier M: Prenatal diagnosis of congenital toxoplasmosis. Lancet 1985;i:500-504.
8. Clyde DF, Shute GR, Press J: Transfer of pyrimethamine in human milk. J Trop Med Hyg 1956;59:277-284.
9. Cook GC: Use of antiprotozoan and anthelmintic drugs during pregnancy: Side-effects and contra-indications. J Infect 1992;25:1-9.
10. Schneider H, Panigel M, Dancis J: Transfer across the perfused placenta of antipyrine, sodium and leucine. Am J Obstet Gynecol 1972; 114:822-828.
11. Challier JC: Criteria for evaluating perfusion experiments and presentation of results; in Schneider H, Dancis J (eds): In vitro Perfusion of Human Placental Tissue. Contrib Gynecol Obstet. Basel, Karger, 1985, vol 13, pp 32-39.
12. Krantz KE, Blakey J, Yoshida K, Romito JA: Demonstration of viability of perfused human term placenta. Obsect Gynecol 1971;37:183-191.
13. Dorangeon PH, Fay R, Marx-Chemla C, Leroux B, Harika G, Dupouy D, Quereux C, Choisy H, Pinon JM, Wahl P: Passage transplacentaire de l'association pyriméthamine-sulfadoxine lors du traitement anténatal de la toxoplasmose congénitale. Presse Méd 1990;19: 2036.
14. Trenque T, Marx C, Quereux C, Leroux B, Dupouy D, Dorangeon PH, Choisy H, Pinon JM: Human maternotbetal distribution of pyrimethamine-sulphadoxince. Br J Clin Pharmacol 1998;45:179-180.
15. Quentin CF, Besnard RM, Bonnard O, Akbaraly R, Brachet-Liermain A, Leng JJ, Bebear C: Etude péliminaire in vitro du passage transplacentaire de la spiramycine. Pathol Biol 1983; 31:425-428.
16. Schoondermark-van de Ven E, Galama J, Vree T, Camps W, Baars I, Eskes T, Meuwissen J, Melchers W: Study of treatment of congenital Toxoplasma gondii infection in rhesus monkeys with pyrimethamine and sulfadiazine. Antimicrob Agents Chemother 1995;39:137-144.
17. Hohlfeld P, Daffos F: Treatment of congenital toxoplasmosis during pregnancy. J Pediatr 1990;116:1003-1005.